Access the full text.
Sign up today, get DeepDyve free for 14 days.
National Cancer Institute. Census tract-level SES database
D. George, E. Heath, A. Sartor, G. Sonpavde, W. Berry, P. Healy, Carolyn Winters, Colleen Riggan, M. Anand, J. Kephart, M. Milowsky, M. Fleming, K. Balaji, Tian Zhang, R. Bitting, M. Harrison, M. McNamara, J. Freedman, S. Halabi, A. Armstrong, D. Bruner (2018)
Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).Journal of Clinical Oncology
K. Yost, C. Perkins, R. Cohen, C. Morris, W. Wright (2001)
Socioeconomic status and breast cancer incidence in California for different race/ethnic groupsCancer Causes & Control, 12
S. Giordano, Y. Kuo, Z. Duan, G. Hortobagyi, J. Freeman, J. Goodwin (2008)
Limits of observational data in determining outcomes from cancer therapyCancer, 112
B. Mahal, A. Aizer, D. Ziehr, A. Hyatt, J. Sammon, M. Schmid, T. Choueiri, Jim Hu, C. Sweeney, C. Beard, A. D'Amico, N. Martin, Simon Kim, Q. Trinh, P. Nguyen (2014)
Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups.Urology, 84 2
Michael Fink, Ulrich Kleeberg, Stefan Bartels (2015)
Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter.The oncologist, 20 7
T. Wilt, M. Brawer, Karen Jones, Michael Barry, W. Aronson, Steven Fox, Jeffrey Gingrich, John Wei, P. Gilhooly, B. Grob, I. Nsouli, P. Iyer, Ruben Cartagena, G. Snider, C. Roehrborn, R. Sharifi, W. Blank, P. Pandya, Gerald Andriole, D. Culkin, T. Wheeler (2012)
Radical prostatectomy versus observation for localized prostate cancer.The New England journal of medicine, 367 3
Elizabeth Ward, A. Jemal, V. Cokkinides, Gopal Singh, C. Cardinez, Asma Ghafoor, M. Thun (2004)
Cancer Disparities by Race/Ethnicity and Socioeconomic StatusCA: A Cancer Journal for Clinicians, 54
F. Brancati, W. Kao, A. Folsom, R. Watson, M. Szklo (2000)
Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study.JAMA, 283 17
J. Mohler, R. Bahnson, B. Boston, J. Busby, A. D'Amico, J. Eastham, C. Enke, D. George, E. Horwitz, R. Huben, P. Kantoff, M. Kawachi, M. Kuettel, P. Lange, G. Macvicar, E. Plimack, J. Pow-Sang, M. Roach, E. Rohren, B. Roth, D. Shrieve, Matthew Smith, S. Srinivas, P. Twardowski, P. Walsh (2010)
NCCN clinical practice guidelines in oncology: prostate cancer.Journal of the National Comprehensive Cancer Network : JNCCN, 8 2
P. Mcgale, D. Cutter, S. Darby, Katherine Henson, R. Jagsi, Carolyn Taylor (2016)
Can Observational Data Replace Randomized Trials?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 27
C. DeSantis, R. Siegel, A. Sauer, K. Miller, S. Fedewa, Kassandra Alcaraz, A. Jemal (2016)
Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparitiesCA: A Cancer Journal for Clinicians, 66
M. Roach, Jiandong Lu, M. Pilepich, S. Asbell, M. Mohiuddin, D. Grignon (2003)
Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials.The Journal of urology, 169 1
Henry Park, S. Lloyd, R. Decker, L. Wilson, James Yu (2012)
Limitations and biases of the Surveillance, Epidemiology, and End Results database.Current problems in cancer, 36 4
P. Bach, D. Schrag, O. Brawley, A. Galaznik, Sofia Yakren, C. Begg (2002)
Survival of blacks and whites after a cancer diagnosis.JAMA, 287 16
V. Murthy, H. Krumholz, C. Gross (2004)
Participation in cancer clinical trials: race-, sex-, and age-based disparities.JAMA, 291 22
E. Feuer, R. Merrill, B. Hankey (1999)
Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.Journal of the National Cancer Institute, 91 12
D. Spratt, Yu-Wei Chen, B. Mahal, J. Osborne, Shuang Zhao, T. Morgan, G. Palapattu, F. Feng, P. Nguyen (2016)
Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes.European urology focus, 2 5
R. Hoffman, Frank Gilliland, J. Eley, L. Harlan, R. Stephenson, J. Stanford, P. Albertson, A. Hamilton, W. Hunt, A. Potosky (2001)
Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.Journal of the National Cancer Institute, 93 5
J. Dignam, Qiang Zhang, M. Kocherginsky (2012)
The Use and Interpretation of Competing Risks Regression ModelsClinical Cancer Research, 18
A. Bill-Axelson, L. Holmberg, H. Garmo, Jennifer Rider, K. Taari, C. Busch, S. Nordling, M. Häggman, S. Andersson, A. Spångberg, O. Andrén, J. Palmgren, G. Steineck, H. Adami, J. Johansson (2014)
Radical prostatectomy or watchful waiting in early prostate cancer.The New England journal of medicine, 370 10
DeSantis (2016)
Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities.CA Cancer J Clin, 66
P. Albertsen, J. Hanley, J. Fine (2005)
20-year outcomes following conservative management of clinically localized prostate cancer.JAMA, 293 17
P. Fontanarosa, H. Bauchner (2018)
Race, Ancestry, and Medical Research.JAMA, 320 15
D. Barocas, D. Penson (2010)
Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gapBJU International, 106
A. Latouche, A. Allignol, J. Beyersmann, M. Labopin, J. Fine (2013)
A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions.Journal of clinical epidemiology, 66 6
F. Hamdy, J. Donovan, J. Lane, M. Mason, C. Metcalfe, P. Holding, M. Davis, Tim Peters, E. Turner, Richard Martin, J. Oxley, M. Robinson, J. Staffurth, E. Walsh, P. Bollina, J. Catto, A. Doble, A. Doherty, D. Gillatt, R. Kockelbergh, H. Kynaston, A. Paul, P. Powell, S. Prescott, D. Rosario, E. Rowe, D. Neal, D. Neal (2017)
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.The New England journal of medicine, 375 15
P. Soni, Holly Hartman, R. Dess, A. Abugharib, S. Allen, F. Feng, A. Zietman, R. Jagsi, M. Schipper, D. Spratt (2019)
Comparison of Population-Based Observational Studies With Randomized Trials in Oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 14
Radiation therapy with or without antiandrogen therapy in treating patients with stage I or stage II prostate cancer
R. D'Agostino, R. D'Agostino (2007)
Estimating treatment effects using observational data.JAMA, 297 3
P. Austin, T. Schuster (2014)
The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: A simulation studyStatistical Methods in Medical Research, 25
R. Jagsi, P. Abrahamse, S. Hawley, J. Graff, A. Hamilton, S. Katz (2012)
Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry dataCancer, 118
G. Mensah, A. Mokdad, E. Ford, K. Greenlund, J. Croft (2005)
State of Disparities in Cardiovascular Health in the United StatesCirculation, 111
T. Freedman, H. Lynch, S. Lemon, S. Tinley, J. Lynch, P. Watson (1997)
Psychologic Aspects of Cancer Genetic Testing: A Research Update for Clinicians
P. Albertsen, D. Moore, W. Shih, Yong Lin, Hui Li, G. Lu-Yao (2011)
Impact of comorbidity on survival among men with localized prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 10
B. Furlow (2015)
US National Cancer Institute investigates PSA coding errors.The Lancet. Oncology, 16 6
S. Halabi, S. Dutta, C. Tangen, M. Rosenthal, D. Petrylak, I. Thompson, K. Chi, J. Araujo, C. Logothetis, D. Quinn, K. Fizazi, M. Morris, M. Eisenberger, D. George, J. Bono, C. Higano, I. Tannock, E. Small, W. Kelly (2019)
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37 5
P. Nguyen, S. Alibhai, S. Basaria, A. D'Amico, P. Kantoff, N. Keating, D. Penson, D. Rosario, B. Tombal, Matthew Smith (2015)
Adverse effects of androgen deprivation therapy and strategies to mitigate them.European urology, 67 5
Key PointsQuestionIs black race associated with worse prostate cancer outcomes after controlling for known prognostic variables and access to care? FindingsIn this multiple-cohort study of 306 100 patients with prostate cancer, black race was not associated with inferior prostate cancer–specific mortality in cohorts from Veterans Affairs health system and National Cancer Institute–sponsored randomized clinical trials. Black race was associated with increased prostate cancer–specific mortality within the Surveillance, Epidemiology, and End Results US population registry, but not in the high-risk subgroup after baseline covariable adjustment, although black race remained associated with increased other-cause mortality. MeaningWith similar access to care and standardized treatment, black men with nonmetastatic prostate cancer appeared to have comparable stage-for-stage prostate cancer–specific mortality to white men.
JAMA Oncology – American Medical Association
Published: Jul 23, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.